NBIX vs OGEN · P/E 45, rev $2.36B vs rev $37.7K
Neurocrine Biosciences Inc (NBIX) versus Oragenics Inc (OGEN) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Oragenics Inc (OGEN) is a biotechnology company listed on US.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported OGEN revenue for 2023-12-31 was $37.7K. Net income was -$20.7M. Revenue was down 71.4% from 2022-12-31 to 2023-12-31. OGEN currently screens at market cap $2.7M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. OGEN currently screens at market cap $2.7M.
Not investment advice. Open the NBIX and OGEN stock pages for the full models.
Not investment advice.